← brief for 2026-09-28 · Slowing decline

Linagliptin increases the expression of LRP2 independent of Nrf2 in streptozotocin-induced diabetic mice.

Key takeaways

This study used mice to test a diabetes drug called linagliptin. It looked at how the drug affects cells in the kidney. The study found the drug changed certain proteins in the mice. This was done in animals, not people, so it is not ready for human use yet.

Who did this work

Promsuwan S (Division of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.) · Takiyama Y (Division of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.) · Takiyama T (Division of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.) · Takiyama Y (Division of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.) · Kitsunai H (Division of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.) · Nomoto H (Division of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.)

Source

Article · Europe PMC, CKD · 2026-09-25
https://doi.org/10.1111/jdi.70454